Interstitial Lung Abnormalities in Renal Transplant Recipients
This trial is active, not recruiting.
|Conditions||renal transplantation, kidney-pancreas transplantation|
|Treatment||high-resolution ct scanning|
|Sponsor||University of Parma|
|Start date||June 2007|
|End date||October 2007|
|Trial size||63 participants|
|Trial identifier||NCT01017757, LungCtRenalTx|
Immunosuppressive drugs such as tacrolimus, cyclosporine, mycophenolate mofetil, sirolimus and everolimus may have toxic pulmonary effects, particularly interstitial alterations. The aim of the present study is to explore the presence of subclinical interstitial lung abnormalities in stable renal transplant recipients taking the different immunosuppressive drugs used as maintenance therapy for renal transplantation.
Subclinical lung alterations as assessed by high-resolution CT scanning
time frame: CT is performed at study entry and, if abnormalities are found, it is repeated at 3-6 months
Male or female participants from 18 years up to 82 years old.
Inclusion Criteria: - Renal transplant patients with stable renal function taking immunosuppressive therapy for at least 24 months and providing written informed consent to participate to the study Exclusion Criteria: - Overt lung disorders, lung toxicity due to other drugs or occupational exposure to lung-toxic agents - Systemic connective tissue disorders or systemic vasculitis
|Official title||Cross-sectional Analysis of Subclinical Interstitial Lung Abnormalities in Stable Renal Transplant Recipients by High-resolution CT Scan|
|Principal investigator||Carlo Buzio, MD|
|Description||Prospective, cross-sectional study examining the high-resolution CT scans obtained in 63 stable renal transplant recipients taking immunosuppressive treatment for at least 24 months. The findings in patients taking the newer immunosuppressive drugs (mycophenolic acid, sirolimus and everolimus) are compared with those of the patients treated in the traditional way (cyclosporine, tacrolimus, azathioprine). All patients undergo high-resolution CT scanning. Eligibility criteria: recipients of kidney or kidney-pancreas transplant, on immunosuppressive therapy for at least 24 months, with stable renal function and absence of any overt lung disease or lung alterations induced by other drugs, systemic diseases or occupational exposure to fibrogenic agents.|
Call for more information